{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52","upperLimit":"88","value":"68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"A Bayesian sequential monitoring design will be used. PFS will be estimated using the Kaplan-Meier method.The length of time interval in months from date of first treatment, during and after the treatment a participant lives without progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Panitumumab 9 mg/kg IV over 60 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.","id":"OG000","title":"Bevacizumab + Capecitabine + Oxaliplatin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants With Progression-free Survival (PFS) at Six Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}